Avenue Therapeutics, Inc.
ATXI- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001644963
No open-market purchases or sales by Avenue Therapeutics, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Avenue Therapeutics, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 14 | 14 | 0 |
| Shares | 448.9K | 456.8K | +7.93K (+1.8%) |
| Value | $520.5K | $532.7K | +$12.2K (+2.4%) |
New holders (6)
Institutions that held Avenue Therapeutics, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Icon Wealth Partners, LLC | 39,992 | $46.6K | 0.01% |
| State Street Corp | 30,593 | $35.8K | 0.00% |
| Renaissance Technologies LLC | 15,982 | $19.0K | 0.00% |
| Shikiar Asset Management Inc | 10,000 | $12.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 8,022 | $9.00K | 0.00% |
| Barrett & Company, Inc. | 15 | $17 | 0.00% |
Sold out (6)
Institutions that held Avenue Therapeutics, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Qube Research & Technologies Ltd | 47,400 | $55.0K |
| Virtu Financial LLC | 32,570 | $38.0K |
| Citigroup Inc | 17,321 | $20.1K |
| Bayesian Capital Management, LP | 11,000 | $12.8K |
| UBS Group AG | 1,246 | $1.45K |
| Bank of America Corp | 12 | $14 |